EGFR and neoplasm: Recent studies have indicated that m5C modification is associated with resistance to targeted therapy.696–698 NSCLC with epidermal growth factor receptor (EGFR) mutations, m5C hypermethylation and NSUN2 are related to the intrinsic gefitinib resistance and tumor recurrence.